With the firm's credentials - to include those of their being an Alumni of JLab New York City - EpiBone is usefully understood as a biomedical engineering company developing technology to enable creation of bone tissue from the patient's own mesenchymal stem cells in vitro for use in bone graft. Effectively, the firm capabilities allows/enable patients to grow their own bone. EpiBones technology utilizes a CT scan of the patients bone defect and the patients own stem cells to construct and cultivate a defect-specific autologous-like bone graft. With close ties to Columbia University, EpiBone is positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year. Rather than the traditional VC route, this firm successfully raised some $5M in from a range of (some well known) private investors and syhdications of specialst investors
